Bone Marrow Transplantation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bone marrow transplantation (BMT) — more precisely called haematopoietic stem cell transplantation (HSCT) — is a procedure in which haematopoietic stem cells (HSCs) are infused intravenously to reconstitute normal blood and immune cell production in patients whose bone marrow is diseased, destroyed by high-dose therapy, or genetically abnormal. The bone marrow contains HSCs capable of generating all blood cell lineages; when these cells fail (due to disease or ablative treatment), BMT provides a new, healthy source of blood-forming cells.

E. Donnall Thomas performed the first successful allogeneic BMT in 1957 and received the Nobel Prize in Physiology or Medicine in 1990 for this work. In the decades since, BMT has evolved from an experimental last resort into the standard curative treatment for over 70 haematological conditions. Modern BMT uses stem cells harvested not only from bone marrow (by direct aspiration under general anaesthesia from the iliac crest) but more commonly from peripheral blood (collected by apheresis after G-CSF mobilisation) or from umbilical cord blood banking.

The BMT process consists of: (1) pre-transplant evaluation and preparation; (2) conditioning — high-dose chemotherapy ± radiotherapy to ablate the patient's bone marrow and suppress immune rejection; (3) transplant day — intravenous infusion of donor stem cells; (4) engraftment phase — 2–4 weeks of neutropenia until donor cells take up residence in the bone marrow and begin producing new blood cells; and (5) post-engraftment recovery including immune reconstitution and management of complications. All BMT is performed at specialist transplant units with dedicated isolation rooms, 24-hour on-call haematology teams, blood bank, and pharmacy.

Allogeneic BMT is the established curative treatment for severe aplastic anaemia (SAA), achieving 80–90% long-term survival with a matched sibling donor in patients under 40; for beta-thalassaemia major and sickle cell disease, where it provides a definitive cure by replacing the genetically defective haematopoietic system; and for primary immunodeficiency disorders including severe combined immunodeficiency (SCID), where it restores immune function.

For malignant haematological conditions, allogeneic BMT provides the graft-versus-leukaemia (GVL) effect — donor T-cells recognising residual malignant cells as foreign and eliminating them — that is not provided by autologous BMT. It is indicated for high-risk AML and ALL in first remission, relapsed AML, myelodysplastic syndromes (MDS), CML refractory to TKIs, and relapsed/refractory T-cell lymphomas. Autologous BMT (using the patient's own stem cells) is used for consolidation of multiple myeloma, relapsed sensitive Hodgkin and non-Hodgkin lymphomas, and certain solid tumours requiring high-dose chemotherapy.

Eligibility for BMT requires comprehensive haematological and medical assessment. For allogeneic BMT: confirmed haematological diagnosis requiring transplantation, adequate organ function (cardiac LVEF above 40–50%, DLCO above 50%, serum creatinine within acceptable range, bilirubin and transaminases within transplant-acceptable limits), performance status ECOG 0–2, disease status in remission or with minimal residual disease, and identification of a suitable donor by HLA typing.

For thalassaemia major, the Pesaro Risk Classification guides eligibility and outcome prediction: Class I patients (no hepatomegaly, no liver fibrosis, regular chelation) have the best outcomes (>90% cure). For paediatric ALL in second remission or high-risk first remission, transplant is offered if a donor is available and the patient is in complete remission. Age eligibility has expanded significantly with reduced-intensity conditioning (RIC), enabling BMT in patients up to age 70–75 at specialist centres. Absolute contraindications include active, uncontrolled infection, progressive malignancy not responsive to salvage therapy, and severe organ dysfunction precluding tolerance of conditioning.

Conditioning regimen selection balances anti-disease efficacy with toxicity tolerance. Myeloablative conditioning (MAC) — cyclophosphamide plus busulfan or total body irradiation — provides complete marrow ablation and maximum anti-leukaemic effect; preferred for younger patients with high-risk malignancies. Reduced-intensity conditioning (RIC) — fludarabine-based regimens — reduces organ toxicity and is preferred for older patients and those with comorbidities, relying more on GVL rather than cytotoxic effect for disease control.

Donor options: Matched sibling donors (25% chance per sibling, 8/10 or 10/10 HLA match) remain the gold standard. Matched unrelated donors are identified through national and international registries (WMDA network — 40+ million volunteers). Haploidentical donors (parents, children, half-matched siblings) with post-transplant cyclophosphamide (PTCy) prophylaxis have dramatically expanded access. Cord blood is used particularly in paediatrics and for patients of non-Caucasian ethnicity lacking suitable unrelated donors. GVHD prophylaxis regimens include calcineurin inhibitors (cyclosporine or tacrolimus) plus methotrexate or mycophenolate mofetil. T-cell depletion strategies — in vivo (ATG, alemtuzumab) and ex vivo (CD34+ selection) — further modulate GVHD risk at the cost of greater immunosuppression and potential for graft failure or relapse. Specific conditioning regimens are selected based on disease, donor type, patient age, and organ function in multidisciplinary BMT team discussion. and review.

For conditions where BMT is the only curative option, it offers transformative outcomes unavailable with any other treatment. Thalassaemia major patients achieving cure through BMT are freed from lifelong transfusion dependence, chelation therapy, and progressive multi-organ iron overload. For severe aplastic anaemia with a matched sibling donor, allogeneic BMT achieves 80–90% long-term survival, far superior to immunosuppressive therapy outcomes in this age group.

For AML with adverse cytogenetics in first remission, allogeneic BMT improves 5-year overall survival from approximately 25% to 45–60% — a doubling of cure rates attributable to the GVL effect. The development of haploidentical BMT with PTCy has made this life-saving option accessible to virtually any patient regardless of donor availability, addressing one of the most significant historical barriers to BMT. Long-term quality-of-life studies of BMT survivors show high levels of wellbeing and functional independence in patients who successfully engraft and do not develop significant GVHD.

Transplant-related mortality (TRM) from infections (bacteraemia, invasive fungal disease, CMV pneumonitis), organ toxicity (hepatic VOD/SOS, interstitial pneumonitis), and GVHD averages 5–20% in modern series. Acute GVHD — affecting skin, gut, and liver within 100 days — occurs in 30–50% of allogeneic BMT patients receiving conventional GVHD prophylaxis, with grade III–IV (severe) GVHD in approximately 10–20% carrying significant mortality risk. Chronic GVHD — a multisystem fibrotic and inflammatory disorder — affects 30–70% of survivors beyond day 100 and is the leading cause of late non-relapse morbidity.

Engraftment failure — primary (stem cells never take) or secondary (initial engraftment followed by loss) — requires emergency re-transplantation or immunosuppressive intervention. Infectious complications during the neutropenic period require prophylactic and preemptive antimicrobial strategies: antibacterial prophylaxis, antifungal prophylaxis (fluconazole or mold-active agents), antiviral prophylaxis (aciclovir for HSV/VZV prevention), and regular CMV PCR surveillance with pre-emptive ganciclovir in high-risk pairs. Late effects including secondary malignancies, endocrine dysfunction, osteoporosis, and cardiovascular disease require long-term specialist follow-up.

Inpatient BMT care in protective isolation lasts from conditioning start until engraftment and clinical stability — typically 4–8 weeks total. After discharge, outpatient monitoring at the transplant centre occurs 2–3 times weekly for 3–6 months. Immunosuppressive agents (calcineurin inhibitor ± mycophenolate) are tapered over 6–12 months post-transplant in the absence of GVHD, with gradual immune reconstitution occurring over 12–24 months.

Disease relapse monitoring uses disease-specific MRD assays (PCR for fusion genes in AML/ALL; chimerism studies; M-protein in myeloma). GVHD assessment and management is ongoing through each clinic visit. Re-vaccination with childhood vaccines (MMR, varicella, pneumococcal, meningococcal) at 12–24 months post-BMT restores acquired immunity. Return to work is typically feasible at 6–12 months in non-GVHD complicated patients.

BMT is one of medicine's most expensive procedures. Allogeneic BMT in the US costs USD 200,000–500,000 for the transplant episode alone; autologous BMT costs approximately USD 100,000–200,000. Post-transplant medications and monitoring add substantial ongoing costs.

India provides world-class BMT at dramatically lower prices. CMC Vellore (Tamil Nadu), Tata Memorial Hospital (Mumbai), Apollo Hospitals, and Narayana Health perform allogeneic BMT at USD 20,000–50,000. Autologous BMT for myeloma is available for USD 10,000–25,000. These centres use the same transplant protocols and medications as leading Western centres and have internationally trained faculty. India is the preferred medical tourism destination for BMT from the Middle East, South Asia, Africa, and Southeast Asia. Singapore (NUH, KKH), Thailand, and Turkey offer BMT at intermediate costs between India and Western prices.

For aplastic anaemia in patients ineligible for BMT or without a suitable donor, immunosuppressive therapy with anti-thymocyte globulin (ATG), cyclosporine, and eltrombopag achieves response in 60–80% of patients. For thalassaemia without a donor, transfusion and chelation maintains acceptable quality of life; gene therapy (Zynteglo/betibeglogene autotemcel) is now approved in eligible patients as an autologous curative alternative to allogeneic BMT. For haematological malignancies, novel targeted therapies and CAR-T cell therapy have emerged as alternatives or bridges to BMT in specific disease settings. Palliative and supportive care are appropriate when curative intent treatment is not feasible. Gene therapy using lentiviral vectors to correct the underlying genetic defect in autologous stem cells (Zynteglo for beta-thalassaemia, betibeglogene autotemcel) offers a curative alternative to allogeneic BMT without GVHD risk, though currently available only at specialised centres.